Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6746MR)

This product GTTS-WQ6746MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6746MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13434MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ2588MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ9640MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ6659MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ1763MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ13716MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ3982MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ3876MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW